Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial
Mocrane Abbar(Université de Montpellier), Fabrice Jollant(Université Paris-Saclay), Ludovic Samalin(Institut Pascal), Christophe Dematteï(Université de Montpellier), Pierre Demaricourt(Université Paris Cité), Pascale Fabbro-Péray(Centre Hospitalier Universitaire de Nîmes), Philip Gorwood(Inserm), Guillaume Vaïva(Inserm), Philippe Courtet(Fondation FondaMental), Wissam El‐Hage(Inserm), Pierre‐Michel Llorca(Institut Pascal), Raphaël Gaillard(Institut Pasteur)
Cited by 177
Related Papers
How mental health care should change as a consequence of the COVID-19 pandemic
|The Lancet Psychiatry|2020|1.9k
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy
|Nature Reviews Drug Discovery|2012|1.3k
The consequences of the COVID-19 pandemic on mental health and implications for clinical practice
|European Psychiatry|2020|1.2k
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder
|The Canadian Journal of Psychiatry|2016|1.1k